Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Updated regulatory timeline for review of MAA in Europe.

PDUFA goal date extension for Nefecon NDA in the U.S.

Interim Report Q2, 2021

Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million

Calliditas Therapeutics intends to carry out a directed share issue

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe

Calliditas secures $75 million term loan facility

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Interim Report Q1, 2021

FDA grants priority review for Nefecon, for patients with IgA nephropathy

Calliditas Therapeutics’ 2020 Annual Report Published

Change in financial calendar

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy

Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

Year-End Report, 2020

Calliditas announces termination of the proposed global offering

Calliditas Therapeutics launches proposed global offering

Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2021